Archive for Healthcare

Heathcare and Biotech Updates

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study

By The Life Science Report

Source: Streetwise Reports   07/01/2020

Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients.

Clinical-stage biotechnology company Akero Therapeutics Inc. (AKRO:NASDAQ), which develops and commercializes treatments for serious metabolic diseases, yesterday announced “results of a 16-week analysis of secondary and exploratory endpoints in its Phase 2a BALANCED study of efruxifermin (EFX), formerly known as AKR-001, in patients with nonalcoholic steatohepatitis (NASH).”

The firm highlighted that “of the 40 treatment responders who had end-of-treatment biopsies, it observed that 48% achieved at least a one-stage improvement in fibrosis without worsening of NAFLD activity score and 28% achieved at least a two-stage improvement in fibrosis.”

Stephen Harrison, M.D., medical director of Pinnacle Clinical Research, remarked, “These substantial improvements observed in multiple measures of liver health, particularly the one- and two-stage improvements in fibrosis, are extremely encouraging and among the strongest biopsy results reported in NASH to date…I believe Efruxifermin continues to set itself apart as one of the most promising drug candidates in NASH, with impressive histology results after just 16 weeks of treatment.”

Akero Therapeutics’ President and CEO Andrew Cheng, M.D., Ph.D., commented, “We believe the BALANCED study data, which exceeded our expectations, demonstrate the strong potential of efruxifermin to be a foundational monotherapy for the treatment of NASH…We look forward to the continued development of efruxifermin and are working diligently to deliver this potentially leading treatment to patients. We are extremely grateful to all of our investigators and study patients, particularly given that this study cohort was completed amidst the COVID-19 pandemic.”

The company advised that the BALANCED study is an ongoing clinical trial in NASH patients and that the firm previously reported that several EFX dose groups in the study had met the primary endpoint compared to placebo.

The Phase 2a BALANCED study enrolled a total of 80 patients and was described as “a multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial in biopsy-confirmed adult patients with NASH.”

The firm explained that NASH (non-alcoholic steatohepatitis) is a serious form of NAFLD (non-alcoholic fatty liver disease) that is closely linked to obesity and diabetes epidemics observed worldwide. The company stated that NASH affects around 17 million Americans and is a leading cause of liver transplants both in the US and Europe.

The company additionally listed that Efruxifermin (EFX) is its lead product candidate for NASH and “it is designed to reduce liver fat and inflammation, reverse fibrosis, increase insulin sensitivity and improve lipoproteins.”

Akero Therapeutics is headquartered in South San Francisco, Calif., and described it business as “a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance to improve overall health.”

Akero Therapeutics started the trading day with a market capitalization of around $714.6 million with approximately 28.67 million shares outstanding. AKRO shares opened 40% higher today at $35.10 (+$10.18, +40.85%) over yesterday’s $24.92 closing price and reached a new 52-week high price this morning of $35.30. The stock has traded today between $31.12 and $35.30 per share and is currently trading at $32.00 (+$7.08, +28.41%).

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: AKRO:NASDAQ,
)

‘Undervalued’ Biopharma Gets Breakthrough Status for Alzheimer’s Agitation Drug

By The Life Science Report

Source: Streetwise Reports   07/01/2020

Axsome Therapeutics’ latest news and clinical outlook are discussed in an H.C. Wainwright & Co. report.

In a June 30 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that the U.S. Food and Drug Administration (FDA) designated Axsome Therapeutics Inc.’s (AXSM:NASDAQ) AXS-05, an NMDA receptor antagonist, a breakthrough therapy for Alzheimer’s disease agitation.

AXS-05 received the same status previously in another indication, major depressive disorder. The designation, in part, means a drug will get priority review, in 6 versus 10 months.

Selvaraju explained that breakthrough designation is “granted to expedite development and review timelines for a promising investigational medicine when preliminary clinical evidence indicates that it may show substantial improvement on one or more clinically significant endpoints over available therapies for a serious or life-threatening condition.”

The analyst indicated that positive data from Axsome’s recent pivotal Phase 2/3 ADVANCE-1 study support the breakthrough designation of AXS-05 for Alzheimer’s disease agitation. In the trial, patients treated with AXS-05 experienced “rapid, substantial, and statistically significant improvement in agitation.” Adverse events, from most to least common, were somnolence, dizziness and diarrhea.

Selvaraju highlighted that H2/20 should be a catalyst-rich period for U.S.-based Axsome, with completion of its regulatory filings for AXS-05 in major depressive disorder and for AXS-07 in migraine, with potential FDA approvals to follow by year-end 2021.

Also next year, clinical data are expected in the way of pivotal AXS-05 results in treatment-resistant depression and possibly Alzheimer’s disease-associated agitation along with Phase 3 AXS-12 findings in narcolepsy.

Selvaraju concluded that Axsome is “still undervalued” and “by 2022 Axsome could have four drugs on the market in the U.S., spanning a total of at least six indications. . .We feel that added clarity from regulators in the wake of multiple FDA meetings that Axsome is likely to have in the course of the coming months should provide significant risk mitigation and substantially increase investor confidence in the company’s clinical development and regulatory approach.”

H.C. Wainwright has a Buy rating and a $210 per share target price on Axsome; the current stock price is $85.02 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from H.C. Wainwright & Co., Axsome Therapeutics Inc., Company Update, June 30, 2020

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

I, Raghuram Selvaraju, Ph.D., certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst’s household has a financial interest in the securities of Axsome
Therapeutics, Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of May 31, 2020 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Axsome
Therapeutics, Inc.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The firm or its affiliates received compensation from Axsome
Therapeutics, Inc. for non-investment banking services in the
previous 12 months.

The firm or its affiliates did receive compensation from Axsome
Therapeutics, Inc. for investment banking services within twelve
months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

 

H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Axsome Therapeutics, Inc. during the past 12 months.

The Firm does not make a market in Axsome Therapeutics, Inc. as of the date of this research report.

( Companies Mentioned: AXSM:NASDAQ,
)

Analyst: G1 Minimizes the Carnage of Chemotherapy

By The Life Science Report

Source: Streetwise Reports   07/01/2020

ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA.

In a June 26 research note, analyst Tony Butler reported that ROTH Capital Partners initiated coverage on G1 Therapeutics Inc. (GTHX:NASDAQ) with a Buy rating and a $55 per share price target. The stock is currently trading at about $24.28 per share.

Butler reviewed the status of the oncology therapeutics firm’s three primary candidates.

G1’s lead drug is trilaciclib, for which it is currently filing a new drug application (NDA) with the U.S. Food and Drug Administration for its use in nonsmall cell lung cancer. The company is expected to complete the application in Q2/20 and commercially launch the therapeutic next year.

For the use of trilaciclib in that indication in the U.S., ROTH models a 75% chance of approval and if approved, peak sales of $500 million. In triple-negative breast cancer, ROTH models $500 million of peak sales and in colorectal cancer, $600 million, both with market entry in 2025-2026.

Butler described trilaciclib as a “CDK4/6 inhibitor that transiently halts cell cycle progression in the bone marrow to ameliorate chemo-induced toxicities. “The primary conclusion from the pooled data support that trilaciclib prior to chemotherapy significantly reduced chemotherapy-induced myelosuppression and was associated with a substantial reduction in high grade hematological treatment-emergent adverse events with no detrimental effects on progression-free survival [PFS] or overall survival [OS]. However, PFS and/or OS were not improved with treatment with trilaciclib. Trilaciclib reduces the toxicity of chemotherapy in SCLC.” Butler noted.

The North Carolina-based biopharma’s second asset in clinical development is rintodestrant. It is an oral, selective estrogen receptor degrader (SERD), for estrogen receptor (ER) positive, HER2 negative breast cancer. “An oral SERD that can rapidly reach steady state, may have utility in ER positive breast cancer,” Butler wrote. This is based on the fact that the combination of fulvestrant, an intramuscular SERD, and palbociclib is a proven therapeutic in the indication. Fulvestrant, which was approved in 2002, attained blockbuster status in 2018, but it is associated with “poor physiochemical properties that require monthly injections leading to less than optimal activity.”

With an estimated market size of ER positive, HER2 negative advanced/metastatic breast cancer patients in the U.S and Europe, ROTH projects peak revenue from both places of $2.1 billion. It projects a rintodestrant launch in 2025-2026.

G1’s third asset is lerociclib, which is also a CDK4/6 inhibitor and which the company is looking to outlicense and market in Europe with a partner, as a treatment for small cell lung, triple-negative breast and colorectal cancers. Recently, G1 entered an exclusive licensing agreement for lerociclib in the Asia-Pacific region, excluding Japan, with Genor Biopharma, a Chinese biopharma.

Finally, Butler reviewed G1 Therapeutics’ financial situation. The company had $242.4 million in cash and cash equivalents at the end of March 2020. Also, it recently entered an agreement with Hercules Capital for up to $100 million in funding for commercialization and further advancement of trilaciclib. The agreement calls for payments to G1 in four tranches, the first of which is $30 million, to be paid upon closing. G1 will receive the remaining tranches when it completes certain milestones.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from ROTH Capital Partners, G1 Therapeutics, Inc., Company Note, June 26, 2020

Regulation Analyst Certification (“Reg AC”): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

ROTH makes a market in shares of G1 Therapeutics, Inc. and as such, buys and sells from customers on a principal basis.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months.

( Companies Mentioned: GTHX:NASDAQ,
)

Biotech’s New Mesothelioma Trial Data Show Efficacy, Immunogenicity

By The Life Science Report

Source: Streetwise Reports   06/24/2020

These results of a study evaluating Targovax’s lead candidate are reviewed and commented on in an H.C. Wainwright & Co. report.

In a June 22 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Targovax ASA’s (TRVX:OSE) ONCOS-102, in trial results, showed efficacy and immunogenicity in malignant pleural mesothelioma (MPM) patients at 12 months post treatment.

ONCOS-102, Targovax’s lead candidate, is an oncolytic adenovirus containing an immune-stimulating transgene. It recently was assessed in the randomized Phase 1/2 trial in combination with standard of care chemotherapy in 31 patients with MPM. In the study, the 20 members of the experimental group received both treatments whereas the 11 in the control group were treated only with standard of care chemotherapy.

Pantginis reviewed the study findings at 12 months and commented, “Given the potent immunogenicity, the data provide a strong rationale for the use of ONCOS-102 to enhance patients’ responses to checkpoint inhibitor regimens and ameliorate outcomes.”

Specifically, the data show that ONCOS-102-treated patients experienced clinical benefits that those in the control group did not experience or experienced to a lesser extent. Those benefits included increased infiltration of cytotoxic T cells in the tumor, upregulation in the expression of genes associated with adaptive immunity and cytotoxicity, polarization of macrophages toward the M1 pro-inflammatory anti-tumor phenotype and increased PD-L1 expression.

The trial results, Pantginis wrote, confirmed the previously reported 8.9 months of median progression-free survival, which compares to 7.6 months among the control group and 5.7–7.3 months historically for standard of care.

The survival rate among the patients who received the treatment combination was encouraging, at 64%, versus 50% among the control group patients, Pantginis noted.

The study findings also confirmed ONCOS-102’s mechanism of action, which is “enhancing immune responses and modulating the tumor microenvironment and its consequent correlation with positive outcomes,” relayed Pantginis. This suggests that “ONCOS-102 in combination with chemotherapy achieves responses with an extent similar to those obtained with CKI.”

As such, Norway-based Targovax next plans to conduct one or more triple combination studies, testing ONCOS-102 plus standard of care chemotherapy plus a checkpoint inhibitor, in firstline MPM patients.

Pantginis concluded that all of the positive mesothelioma data Targovax has accumulated to date “provide strong rationale for moving mesothelioma forward as first path to market.”

H.C. Wainwright & Co. has a Buy rating and an NOK19 per share price target on Targovax, the stock of which is currently trading at about NOK7.32 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures from H. C. Wainwright, Targovax ASA, Company Update, June 22, 2020

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

I, Joseph Pantginis, Ph.D., certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst’s household has a financial interest in the securities of Targovax ASA (including, without limitation, any option, right, warrant, future, long or short position).

As of May 31, 2020 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Targovax ASA.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The Firm or its affiliates did not receive compensation from Targovax ASA for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

The Firm does not make a market in Targovax ASA as of the date of this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

( Companies Mentioned: TRVX:OSE,
)

Translate Bio and Sanofi Expand Partnership to Develop mRNA Vaccines

By The Life Science Report

Source: Streetwise Reports   06/23/2020

Translate Bio shares traded 45% higher reaching a new 52-week high after the company reported that it is expanding its collaboration with Sanofi Pasteur to develop mRNA vaccines across all infectious disease areas.

Clinical-stage messenger RNA (mRNA) therapeutics company Translate Bio Inc. (TBIO:NASDAQ) and Sanofi Pasteur, the vaccines global business unit of Sanofi SA (SNY:NYSE), today announced that “the two firms have agreed to expand their existing 2018 collaboration and license agreement to develop mRNA vaccines for infectious diseases.”

The companies advised that under the terms of the expanded agreement, “Translate Bio will receive a total upfront payment of $425 million, consisting of a $300 million cash payment and a private placement common stock investment of $125 million at $25.59 per share representing a 50 percent premium to the 20-day moving average share price prior to signing.” Translate Bio will also be eligible to receive additional payments up to $1.9 billion if certain milestones are met as stipulated in the terms of the 2018 agreement.

Sanofi Pasteur will be responsible for all costs during the collaboration term and in return will receive the exclusive worldwide rights for infectious disease vaccines.

Sanofi Pasteur’s EVP Thomas Triomphe remarked, “As all eyes are on prevention of infectious disease through vaccines, this is a pointed moment in time where we are called upon to seek innovative ways to protect public health…We are excited by the novel technology and expertise Translate Bio brings, and we believe that adding this mRNA platform to our vaccines development capabilities will help us advance prevention against current and future infectious diseases.”

Ronald Renaud, CEO of Translate Bio, commented, “The expansion of our collaboration with Sanofi Pasteur validates the progress we’ve made in the development of mRNA vaccines for infectious diseases since our work together began in 2018 and also speaks to the potential of our mRNA platform. We are excited to work with Sanofi in this broadened capacity with the goal of ultimately delivering vaccines on a global scale, a need underscored by the current pandemic…Translate Bio will also be well positioned financially to continue to build upon our internal capabilities with a focus on advancing innovations in platform discovery and on the development of ongoing and additional preclinical therapeutic programs as we aim to bring multiple programs towards clinical development.”

Under the collaboration agreement terms, Translate Bio is employing its mRNA platform to create and manufacture vaccine candidates and Sanofi Pasteur is providing vaccine expertise to accelerated and advance vaccine candidates through development.

The teams are already working together on several COVID-19 vaccine candidates in vivo for immunogenicity and neutralizing antibody activity to support lead candidate selection and the companies hope to initiate a first-in-human clinical trial in Q4/20.

The Sanofi Pasteur and Translate Bio collaboration was initially formed in 2018, whereby Translate Bio entered into an exclusive license agreement with Sanofi Pasteur to develop mRNA vaccines for up to five infectious disease pathogens. The agreement was later expanded to include the collaborative development of a novel mRNA vaccine for COVID-19 in March 2020.

Sanofi, based in Paris, is a $131.0 billion market cap global biopharmaceutical company involved in research, development, manufacture and marketing of therapeutic solutions. The firm employs more than 100,000 people in 100 countries.

Translate Bio is a clinical-stage mRNA therapeutics company headquartered in Lexington, Mass. The firm concentrates its efforts on developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. Translate Bio is mostly focused utilizing it technology to treat pulmonary diseases caused by insufficient protein production or where the reduction of proteins can modify disease.

Translate Bio began the day with a market capitalization of around $1.0 billion with approximately 62.91 million shares outstanding and a short interest of about 2.9%. TBIO shares opened 52% higher today at $24.69 (+$8.45, +52.03%) over yesterday’s $16.24 closing price and reached a new 52-week high price this morning of $27.24. The stock has traded today between $21.56 and $27.24 per share and is currently trading at $23.60 (+$7.36, +45.32%).

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: TBIO:NASDAQ,
)

Invitae Corp. Enters into Definitive Agreement to Acquire ArcherDX

By The Life Science Report

Source: Streetwise Reports   06/22/2020

Shares of Invitae Corp. traded 40% higher after the company reported it will acquire ArcherDX in a combination cash and stock deal valued at around $1.4 billion.

Advanced medical genetics company Invitae Corp. (NVTA:NYSE) and genomics analysis firm ArcherDX today announced that “the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology.”

The firms indicated that the combined entity will be positioned strongly to transform cancer patients’ overall care. The companies stated that the merger will integrate germline testing, tumor profiling and liquid biopsy technologies and services in a single platform, which will facilitate precision personalized oncology approaches from diagnostic testing to therapy optimization and monitoring. The combined organization’s centralized and local testing capabilities will service customers in more than 95 markets.

Invitae’s co-founder and CEO Sean George, Ph.D., commented, “From the beginning, Invitae’s goal has been to aggregate the world’s genetic tests into a single platform in service of our mission to bring comprehensive genetic information into mainstream medicine. Today, we take another major step forward in that effort.”

Jason Myers, Ph.D., CEO and co-founder of ArcherDX, remarked, “We are thrilled to unite with Invitae to form the leading hub for precision oncology, diagnostics, therapy optimization and monitoring, with an opportunity to accelerate both patient care and shareholder value…ArcherDX was founded to democratize precision oncology with best-in-class products that are personal, actionable and available in local care settings…ArcherDX products, workflow and powerful bioinformatics solutions provide an opportunity to advance precision oncology into regional and community settings and address an estimated $45 billion market opportunity. Together with Invitae, we look forward to expanding our impact beyond oncology, driving significant value through shared expertise to inform healthcare throughout life, globally.”

Invitae’s Dr. George added, “Integrating all aspects of cancer genetics can transform care for patients and the flexibility that comes from both centralized and decentralized capabilities will uniquely position Invitae to meet the needs of customers worldwide…By joining together, we will unite world-class capabilities in the hands of a talented team with complementary expertise and strong brands in service of a shared goal to improve healthcare for patients.”

Under the terms of the agreement, “Invitae will acquire ArcherDX for upfront consideration consisting of 30 million shares of Invitae common stock and $325 million in cash, plus up to an additional 27 million shares of Invitae common stock payable in connection with the achievement of certain milestones, for an overall transaction valued at approximately $1.4 billion.”

The companies advised that the transaction, which is subject to customary closing conditions including approval by the stockholders of Invitae and ArcherDX, has already been unanimously approved by the boards of directors of both companies and is expected to close in several months.

Invitae Corp. is a medical genetics company based in San Francisco. The company listed that “its mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.” The firm is focused on strives to aggregating the world’s genetic tests into a single service with quicker turnaround, higher quality and lower prices.

ArcherDX is headquartered in Boulder, Colo., and was described in the new release as “a leading genomic analysis company democratizing precision oncology through a suite of products and services that are highly accurate, personal, actionable and easy to use in local settings.” The firm develops and commercializes research products which are later integrated into in vitro diagnostic (IVD) products. The company has IVD products currently in development for solid tumor biomarker identification and Personalized Cancer Monitoring.

Invitae Corp. started off the day with a market capitalization of around $2.3 billion with approximately 125.0 million shares outstanding and a short interest of about 16.7%. NVTA shares opened nearly 18% higher today at $22.02 (+$3.31, +17.69%) over Friday’s $18.71 closing price. The stock has traded today between $21.50 and $27.77 per share and is currently trading at $26.69 (+$7.98, +42.65%).

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: NVTA:NYSE,
)

FDA Grants Ampio Pharma Approval to Begin Phase 1 Trial in COVID-19 Patients

By The Life Science Report

Source: Streetwise Reports   06/19/2020

Ampio Pharmaceuticals’ shares traded higher after the company reported that the FDA cleared the firm to proceed with human trials of its Investigative New Drug application for intravenous AmpionTM for treatment in COVID-19 affected patients on supplemental oxygen.

Biopharmaceutical company Ampio Pharmaceuticals Inc. (AMPE:NYSE.American), which is engaged in advancing immunology-based therapies for prevalent inflammatory conditions including developing therapies for patients infected with the SARS-CoV-2 virus (COVID-19), today announced that “The U.S. Food and Drug Administration (FDA) completed its review of the Company’s Investigative New Drug (IND) application for intravenous (IV) AmpionTM treatment for COVID-19 affected patients and has cleared the company to proceed with human trials.”

The firm advised that it will be starting a Phase 1 clinical study to evaluate IV Ampion as a treatment for COVID-19 patients on supplemental oxygen. The company advised that “the need for supplemental oxygen in COVID-19 patients is indicative of an inflammatory process in the lungs and that as an immunomodulatory anti-inflammatory agent, Ampion may be effective in interrupting the inflammatory cascade associated with COVID-19 and improving the clinical course and outcome of patients.”

The company further explained that “years of extensive in-vitro studies on cell cultures have confirmed that the mechanism of action of Ampion may be suitable for the treatment of inflammatory conditions, such as acute respiratory distress syndrome and the cytokine storm, associated with COVID-19.”

Ampio Pharmaceuticals is a development stage biopharmaceutical company headquartered in Englewood, Colo. The firm concentrates it efforts mostly on developing its Ampion product candidate to address the treatment of prevalent inflammatory conditions for which currently there are limited treatment options. The company stated that “its lead drug, Ampion, is backed by an extensive patent portfolio with intellectual property protection extending through 2032, and will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act.” In addition to treating inflammatory conditions, the company states on its website that it is also developing compounds to address several other areas of significant unmet medical needs in the areas of osteoarthritis and diabetic macular edema.

Ampio Pharmaceuticals has a market capitalization of around $94.0 million with approximately 164.9 million shares outstanding and a short interest of about 7.7%. AMPE shares opened 40% higher today at $0.81 (+$0.57, +42.11%) over yesterday’s $0.57 closing price. The stock has traded today between $0.6062 and $0.85 per share and is currently trading at $0.6339 (+$0.0639, +11.21%).

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: AMPE:NYSE.American,
)

Alpine Immune Shares Soar 160% on Global Option and License Agreement with AbbVie

By The Life Science Report – Source: Streetwise Reports   06/18/2020

Shares of Alpine Immune Sciences set a new 52-week high after the company reported that it entered into an exclusive worldwide option and license agreement with AbbVie Inc. to develop and commercialize ALPN-101.

Clinical-stage immunotherapy company Alpine Immune Sciences Inc. (ALPN:NASDAQ) and AbbVie Inc. (ABBV:NYSE) today announced “an exclusive worldwide option and license agreement for ALPN-101, a first-in-class dual CD28/ICOS costimulation antagonist.”

Under the terms of the agreement, Alpine Immune Sciences will grant AbbVie option to license exclusive worldwide rights for ALPN-101. This will enable AbbVie to build upon its continued efforts to develop novel therapies in immunology. Alpine Immune Sciences will receive $60 million in an upfront cash payment and is additionally eligible to receive up to $805 million for exercise of the option and if certain success-based development, regulatory and commercial objectives and milestones are met.

The report indicated that Alpine Immune Sciences will be conducting a phase 2 study in systemic lupus erythematosus during the option period. Upon exercise of the option, AbbVie would then conduct all future clinical development, manufacturing and commercialization activities for ALPN-101.

The company explained that “CD28 and ICOS are key costimulatory molecules that likely play critical roles in multiple autoimmune and inflammatory diseases and that ALPN-101 is a potent inhibitor of both CD28 and ICOS pathways with demonstrated efficacy in multiple preclinical disease models, superior to blockade of either pathway alone.”

The company’ Executive Chairman and CEO Mitchell H. Gold, M.D., commented, “We are very pleased to partner ALPN-101 with AbbVie, a world leader in the development and commercialization of innovative immunology therapies…AbbVie is an ideal partner for ALPN-101, with the therapeutic area expertise, R&D commitment, and global resources needed to maximize ALPN-101’s potential for patients suffering from autoimmune diseases. Today’s agreement validates our unique Directed Evolution platform that has yielded multiple product candidates, including ALPN-101. We look forward to working with our colleagues at AbbVie to potentially transform clinical outcomes in systemic lupus erythematosus, a disease with currently few appealing treatment options.”

AbbVie’s SVP and Chief Scientific Officer Tom Hudson, M.D., remarked, “AbbVie’s expertise in Immunology has led to remarkable breakthroughs in the treatment of autoimmune diseases…ALPN-101’s dual mechanism of action has compelling potential as a next-generation treatment in systemic lupus erythematosus and other autoimmune diseases. We are excited to partner with the team at Alpine on the development of this novel therapeutic.”

Alpine Immune Sciences is a clinical stage biopharmaceutical company headquartered in Seattle. The firm is engaged in the development of multifunctional immune therapeutics to improve patients’ lives using unique protein engineering technologies.

AbbVie is a global biopharmaceutical and healthcare company based in North Chicago, Ill., with a market cap of greater than $168 billion. The company’s products address key therapeutic areas including eye care, gastroenterology, immunology, neuroscience, oncology, virology and women’s health, as well as products and services throughout its Allergan Aesthetics portfolio.

Alpine Immune Sciences started the day with a market capitalization of around $86.6 million with approximately 18.59 million shares outstanding. APLN shares opened more that 200% higher today at $14.05 (+$9.59, +215.02%) over yesterday’s $4.46 closing price and reached a new 52-week high price this morning of $15.00. The stock has traded today between $8.70 and $15.00 per share and is currently trading at $12.72 (+$7.86, +161.29%).

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: ALPN:NASDAQ,
)

Regenerative Medicine Firm Reports Early Results from COVID-19 Trials

By The Life Science Report

Source: Streetwise Reports   06/17/2020

Pluristem Therapeutics’ coronavirus clinical studies and financing are discussed in a Dawson James report.

In a June 11 research note, Dawson James analyst Jason Kolbert reported that Pluristem Therapeutics Inc. (PSTI:NASDAQ) announced the status of COVID-19-infected patients 28 days after treatment with its PLX cells.

Results are for seven patients who reached the 28-day follow-up after receiving Pluristem’s PLX cells through a compassionate use program in Israel and the sole patient of an expanded access program in the U.S. When these individuals were treated, all of them were inpatients in intensive care units (ICUs), on ventilator support and suffering acute respiratory distress syndrome (ARDS) symptoms.

Kolbert highlighted that the survival rate among these treated patients at day 28 was 87.5%. Three-quarters of the patients were able to get off of mechanical ventilation, not needing it anymore, and 62.5% of them were discharged from the hospital, alive.

To date, 18 patients received PLX cells, but the remaining 10 of them have not yet reached 28 days.

Kolbert relayed that in other news, another trial commenced that is testing Pluristem’s PLX-PAD as a treatment of severe, ARDS-complicated COVID-19 cases. This is a U.S.-based, a 140-patient, multicenter (up to 25 sites), randomized, double-blind, placebo-controlled, Phase 2 study in which PLX cells will be administered intramuscularly.

The trial’s primary endpoint is the number of ventilator-free days the patients have during the first 28 days. The secondary endpoints are mortality, duration of mechanical ventilation, number of ICU-free days and number of hospitalization-free days.

In a third piece of news, Kolbert noted, the European Union approved €50 million in nondilutive financing for Israel-based Pluristem, which it is to use to develop its PLX platform, specifically as a treatment for COVID-19 complications. Pluristem will receive these monies in three tranches, the first of which is €20 million, as it achieves certain milestones.

Dawson James has a Buy rating and a $12 per share target price on Pluristem, the stock of which is currently trading at about $7.48 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures for Dawson James Securities, Pluristem Therapeutics, June 11, 2020

The Firm does not make a market in the securities of the subject company(s). The Firm has NOT engaged in investment banking
relationships with PLURISTEM THERAPEUTICS in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has NOT received any other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of May 31, 2020, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm’s investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Analyst Certification: The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

( Companies Mentioned: PSTI:NASDAQ,
)

Edesa Shares Double Upon Gaining Approval to Initiate Phase 2/3 COVID-19 Study

By The Life Science Report – Source: Streetwise Reports   06/15/2020

Shares of Edesa Biotech traded more than 100% higher after the company reported that it had received regulatory approval from Health Canada to initiate a Phase 2/3 study of its investigational drug EB05 in COVID-19.

Clinical-stage biopharmaceutical company Edesa Biotech Inc. (EDSA:NASDAQ), which is focused on developing treatments for inflammatory and immune-related diseases, today announced that “it has received expedited approval from Health Canada to begin a Phase 2/3 clinical study of its investigational drug, EB05, which the company is developing as a potential treatment for moderate to severe COVID-19 patients.”

The firm indicated that it a has sufficient EB05 drug product available now and plans to begin the study at up to 30 sites. The company advised that it is also currently seeking government grants to accelerate the commencement and roll out of the study.

The company explained that “EB05 is a monoclonal antibody that has demonstrated the ability to suppress the release of proinflammatory cytokines that are often observed in severe COVID-19 patients and that specifically, the drug inhibits toll-like receptor 4 (TLR4) signaling – a key component of the innate immune system and an important mediator of inflammation responsible for acute lung injury that has been shown to be activated during SARS and Influenza infection.”

The firm stated that it plans to enroll as many as 355 patients in the first phase of the Phase 2/3 EB05 trial, which is planned to be a multi-location study to evaluate the efficacy and safety of EB05 in moderate to severe adult hospitalized COVID-19 patients.

The company’s CEO Dr. Par Nijhawan commented, “Health Canada’s expedited review process and subsequent approval of our Clinical Trial Application represents a significant step in developing new drugs that can treat the underlying conditions induced by the SARS-CoV-2 infection…We greatly appreciate the actions being taken by the government to expedite COVID-19 applications and provide support for clinical studies.”

Edesa Biotech is a clinical-stage biopharmaceutical company based in Markham, Ontario, and also has offices in the U.S. located in southern Calif. The firm develops treatments for inflammatory and immune-related diseases particularly those with clear unmet medical needs.

Edesa Biotech started off the day with a market capitalization of around $25.7 million with approximately 8.859 million shares outstanding. EDSA shares opened 140% higher today at $6.97 (+$4.07, +140.34%) over Friday’s $2.90 closing price. The stock has traded today between $5.80 and $10.00 per share and is currently trading at $6.17 (+$3.27, +112.76%).

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: EDSA:NASDAQ,
)